Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/17/2017 03/20/2017 03/21/2017 03/22/2017 03/23/2017 Date
14.35(c) 14.15(c) 13.9(c) 13.95(c) 14.1 Last
791 563 394 397 1 031 354 920 329 412 129 Volume
-1.37% -1.39% -1.77% +0.36% +1.08% Change
More quotes
Financials ($)
Sales 2017 169 M
EBIT 2017 -27,9 M
Net income 2017 -21,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 204 M
EBIT 2018 0,71 M
Net income 2018 1,12 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 3,67x
Capi. / Sales2018 3,03x
Capitalization 619 M
More Financials
Company
Vanda Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products.It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder.Its product portfolio includes HETLIOZ,... 
More about the company
Surperformance© ratings of Vanda Pharmaceuticals Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on VANDA PHARMACEUTICALS INC.
03/13 VANDA PHARMACEUTICALS INC. (NASDAQ : VNDA) Files An 8-K Departure of Directors o..
03/13 VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
03/06 VANDA PHARMACEUTICALS INC. : Change in Directors or Principal Officers (form 8-K..
03/06 VANDA PHARMACEUTICALS : Announces Participation at March 2017 Investor Conferenc..
03/03 VANDA PHARMACEUTICALS : Federal Contracts Awarded to Companies in District of Co..
03/03 VANDA PHARMACEUTICALS : CONTRACT AWARD - 65-- Vanda Pharmaceuticals 03-01-2017-0..
03/03 VANDA PHARMACEUTICALS : $1.96 Million Federal Contract Awarded to Vanda Pharmace..
02/17 VANDA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
02/15 VANDA PHARMACEUTICALS : reports 4Q loss
02/15 VANDA PHARMACEUTICALS INC. : Results of Operations and Financial Condition, Fina..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/22Vanda Pharmaceuticals (VNDA) Presents At Oppenheimer 27th Annual Healthcare C.. 
03/10Get the latest news and updates for $KALV $ACLZ $ZBRA $OKS $VNDA automaticall.. 
03/08Vanda Pharmaceuticals (VNDA) Presents At Cowen and Company 37th Annual Health.. 
03/06Vanda Pharmaceuticals : Announces Participation at March 2017 Investor Confer.. 
03/02Vanda: Investing For Growth  
More tweets
Qtime:18
News from SeekingAlpha
03/22 Vanda Pharmaceuticals (VNDA) Presents At Oppenheimer 27th Annual Healthcare C..
03/08 Vanda Pharmaceuticals (VNDA) Presents At Cowen and Company 37th Annual Health..
03/02 VANDA : Investing For Growth
02/15 Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2016 Results - ..
02/15 Vanda Pharmaceuticals beats by $0.08, misses on revenue
Advertisement
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | VNDA | US9216591084 | 4-Traders
Full-screen chart
Technical analysis trends VANDA PHARMACEUTI...
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 22,3 $
Spread / Average Target 59%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Senior VP
Paolo Baroldi Chief Medical Officer & Senior Vice President
Vincent J. Milano Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS ..-12.54%619
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
REGENERON PHARMACEUTIC..0.56%39 159
ACTELION LTD24.49%29 874
More Results